FDA Extends Comment Period For Direct-To-Consumer Advertising Guidances
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency has reopened the comment period until Aug. 10 to allow additional time for conducting DTC research, Ad Division Director Tom Abrams says. FDA plans to conduct its own research on the content and format of the brief summary.
You may also be interested in...
FDA Should Allow Linkages Between "Help-Seeking" and Full Product Ads, Pfizer Says
Similarities between disease awareness ads and full product ads, which contain risk information, could benefit consumers, Pfizer says in comments on FDA's draft DTC guidance. The company is working with consumer and medical groups to generate such evidence.
FDA Should Allow Linkages Between "Help-Seeking" and Full Product Ads, Pfizer Says
Similarities between disease awareness ads and full product ads, which contain risk information, could benefit consumers, Pfizer says in comments on FDA's draft DTC guidance. The company is working with consumer and medical groups to generate such evidence.
DTC Brief Summary: Consumers Prefer Q&A Format, Researcher Tells FDA
University of Georgia professor says consumers reacted negatively to use of a prominent risk information window in print ads. FDA ad division official questions whether a drug’s efficacy information should be included in the brief summary.